Clinical trials: Androgens
Prostate Cancer
Pembro With Radiation With or Without Olaparib
This trial will evaluate whether the immune-sensitizing effects of immunotherapy (Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the effects of immunotherapy in men with high-risk localized…
- Trial name
- NCT05568550
- Testing
- Pembrolizumab, Olaparib, Androgen Deprivation Therapy
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Zin W Myint
Prostate Cancer, Insulin Resistance
Pioglitazone and Insulin Resistance in ADT
This study is being done to establish the mechanisms underlying insulin resistance (reduced insulin action that can lead to high blood sugar and maybe diabetes) in patients undergoing androgen deprivation therapy (ADT) for…
- Conditions
- Prostate Cancer, Insulin Resistance, Diabetes Mellitus, Type 2, Androgen Deficiency
- Trial name
- NCT05098327
- Testing
- Pioglitazone 30 mg
- Where
- United States
- Sponsor
- State University of New York at Buffalo
Androgen Receptor Positive, Estrogen Receptor Negative
Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer
This phase II trial studies the side effects and how well pembrolizumab and enobosarm work in treating patients with androgen receptor positive triple negative breast cancer that has spread to other places in the body…
- Conditions
- Androgen Receptor Positive, Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT02971761
- Testing
- Enobosarm, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Cancer of the Prostate
PCa Patients Managed With ADT to Examine the Effect of Nutritional Guidance and Aerobic/Resistance Fitness Training
The purpose of this observational study is to examine the level of activity in the prostate cancer population treated with Androgen Deprivation Therapy (ADT).
- Trial name
- ELIFIT (NCT04057859)
- Where
- 23 sites in Canada
- Volunteers
- 271 people
- Sponsor
- CMX Research
Prostate Cancer, Androgen Deprivation Therapy
Feasibility and Safety of Physical Exercise in Men With Prostate Cancer
Prostate cancer (PCa) is among the most widespread in the male population and represents 19% of all cancers diagnosed from the age of fifty, in Italy.
- Conditions
- Prostate Cancer, Androgen Deprivation Therapy, Radiotherapy
- Trial name
- PCa_Ex (NCT04500080)
- Testing
- PE Intervention
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Prostate Cancer
Assessment of Bone Loss in Men Receiving Treatment for Prostate Cancer
The ANTELOPE trial is a longitudinal observational clinical study of changes in bone density, structure and strength over 12 months in men receiving treatment for prostate cancer.
- Trial name
- ANTELOPE (NCT02785627)
- Testing
- Comprehensive bone health assessment
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Prof Janet Brown
Triple Negative Breast Cancer, Metastatic Breast Cancer
Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
The goal of this clinical trial is to evaluate the efficacy of investigator's choice of chemotherapy, either alone or in combination with everolimus, in treating patients with locally recurrent inoperable or metastatic…
- Conditions
- Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation
- Trial name
- BCTOP-T-M03 (NCT05954442)
- Testing
- Everolimus, Investigator's Choice of Chemotherapy
- Where
- China
- Volunteers
- 203 people
- Sponsor
- Fudan University
Prostate Cancer
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.
- Trial name
- S1216 (NCT01809691)
- Testing
- TAK-700, Bicalutamide
- Where
- 560 sites in United States
- Volunteers
- 1,313 people
- Sponsor
- SWOG Cancer Research Network
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer
This phase I/II trial studies the side effects and best dose of calcitriol when given in combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in treating patients with prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00536991
- Testing
- Calcitriol, Ketoconazole, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Roswell Park Cancer Institute
Castrate-Resistant Prostate Cancer
Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
This study is designed to assess the safety and tolerability of atezolizumab when given in combination with radium-223 dichloride in participants with metastatic CRPC who have progressed after treatment with an androgen pathway…
- Trial name
- NCT02814669
- Testing
- Atezolizumab, Radium-223 Dichloride
- Where
- 17 sites in United States
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Hypogonadism, Male, Testosterone Deficiency
Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men
This study relates to men with hypogonadism, a condition describing a deficiency of androgens such as testosterone. Deficiency of these hormones occurs in men due to testicular (primary) or hypothalamic-pituitary (secondary)…
- Conditions
- Hypogonadism, Male, Testosterone Deficiency, Prostate Cancer, Androgen Deficiency
- Trial name
- MMetdMH (NCT05773183)
- Testing
- Testosterone, GnRH
- Where
- Ireland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Royal College of Surgeons, Ireland
Prostate Cancer
An Alternative to A Fixed Schedule In Management Of Prostate Cancer
The male sex-hormone called testosterone is known to play a key role in the growth of prostate cancer. The usual treatment for the disease involves suppression of hormones (testosterone) by anti-hormonal treatment for an unknown…
- Trial name
- TADS (NCT01056562)
- Where
- Canada
- Volunteers
- 82 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as leuprolide, goserelin, flutamide, or bicalutamide, may stop the adrenal glands from making androgens.
- Trial name
- NCT00006359
- Testing
- LHRH agonist, antiandrogen, radiation therapy
- Where
- 26 sites in United States
- Volunteers
- 63 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
This partially randomized phase II trial is studying how well giving bicalutamide together with RO4929097 works in treating patients with previously treated prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01200810
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, bicalutamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer
This research study is studying the use of a targeted therapy called LY SARM, which is an investigational drug from a new class of molecules called Selective Androgen Receptor Modulators (SARMs) as a possible improvement in…
- Trial name
- NCT02499497
- Testing
- LY2452473
- Where
- 4 sites in United States
- Volunteers
- 114 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer, Cardiovascular Diseases
CV CARE: CardioVascular Care in PC Patients
This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting androgen deprivation therapy (ADT), with the goal of integrating a…
- Trial name
- NCT06202820
- Testing
- CV Care Program
- Where
- 2 sites in United States
- Volunteers
- 180 people
- Sponsor
- Dana-Farber Cancer Institute
Prostatic Neoplasms
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
The purpose of this study is to evaluate the efficacy, based on prostate-specific antigen (PSA) progression, of abiraterone acetate in participants with metastatic (spread of cancer cells from one part of the body to another)…
- Trial name
- NCT02217566
- Testing
- Abiraterone acetate, Prednisone, Androgen deprivation therapy (ADT)
- Where
- 4 sites in Brazil
- Volunteers
- 46 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
The purpose of this study is to establish the maximum tolerable dose of niraparib when combined with prostate stereotactic body radiotherapy (SBRT), abiraterone, leuprolide, and prednisone (the phase 1 portion of the study) and…
- Trial name
- ASCLEPIuS (NCT04194554)
- Testing
- Niraparib, Leuprolide, Abiraterone Acetate
- Where
- 6 sites in United States
- Volunteers
- 102 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Cancer
Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer
RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying vaccine therapy to see how well it works compared with a…
- Trial name
- NCT00514072
- Testing
- BCG vaccine, prostate cancer vaccine ONY-P1
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Kael-GemVax Co., Ltd.
Spinal Cord Injury, Spinal Cord Injuries
Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial
Spinal cord injury (SCI) results in lower limb muscle loss, bone loss, and high fat mass that impede the recovery of physical function, increase bone fracture risk, and worsen health and quality of life.
- Conditions
- Spinal Cord Injury, Spinal Cord Injuries, Injuries, Spinal Cord, Spinal Cord Contusion
- Trial name
- TRT-SCI (NCT07742553)
- Testing
- testosterone cypionate, finasteride
- Where
- 4 sites in United States
- Volunteers
- 300 people
- Sponsor
- VA Office of Research and Development
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.